"There's a lot of hope and hype still in the microbiome sphere," Ferring's president Per Falk tells Scrip, but the rewards could be considerable for companies that can deliver well-documented safety and efficacy data and do not take try to take shortcuts.
Ferring Pharmaceuticals AS president Per Falk has been reflecting on the journey thus far for microbiome-based drugs and why there is no substitute for rigorous clinical data.
Speaking to Scrip hours before the Swiss company unveiled the world’s first positive Phase III results for any microbiome-based therapy...
Create an account to read this article
Already a subscriber?
Recent moves in the industry include C-suite changes at Galapagos, plus Bristol Myers Squibb gets a new CMO from AstraZeneca.
François Roger believes fixing inefficiencies is more important than playing with pricing.
Pharma companies like Sarepta, Replimune and Capricor made gains on Wall Street after news broke that the FDA Center for Biologics Evaluation and Research director Vinay Prasad is leaving.
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.
AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.
Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.
